Katarina Luptakova
Chief Tech/Sci/R&D Officer at XILIO THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Profile
Katarina Luptakova is currently the Chief Medical Officer at Xilio Therapeutics, Inc. She previously worked as the Senior Medical Director at Tesaro, Inc. and as the Vice President-Clinical Development at Constellation Pharmaceuticals, Inc. She holds a doctorate degree from the University of Commenius.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
XILIO THERAPEUTICS INC
-.--% | 2024-04-30 | 0 ( -.--% ) | - $ | 2024-03-30 |
Katarina Luptakova active positions
| Companies | Position | Start |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-09-30 |
Former positions of Katarina Luptakova
| Companies | Position | End |
|---|---|---|
| TESARO INC | Chief Tech/Sci/R&D Officer | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Katarina Luptakova
| University of Commenius | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Katarina Luptakova